(ESMO) Congress 2016: Highlights/summary of selected abstracts in gyn cancers Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, December 23, 2016

(ESMO) Congress 2016: Highlights/summary of selected abstracts in gyn cancers



open access

Conclusion
Two strong themes emerged from the gynecological track at ESMO
2016. Firstly, the therapeutic landscape for PARP inhibitors is expanding
beyond the treatment of gBRCAmut HGSOC. HRD assays may usefully
identify patients likely to have the greatest response to PARP inhibitor
treatment, but may not be sufficiently sensitive to separate out nonresponders
to PARP inhibitors from within the HRD negative group.
The niraparib trial provides additional evidence that there is a clinical
benefit for PARP inhibitor maintenance therapy in most patients with
platinum sensitive recurrent disease. Secondly, there are number of
novel therapies, includingADCs and smallmoleculeswhich are showing
promising preliminary activity in platinum-resistant ovarian cancer,
where a minimal gain in outcome has been made in the past decade.

Details of all of the ESMO abstracts can be found at: http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf

0 comments :

Post a Comment

Your comments?